Payment overview · 2025
General Payments
$224.17
11 reported records · 7 companies
Healthcare provider profile · identity verified
Emerald S Tay, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · SAN GABRIEL, CA · NPI 1255331294
Verified facts
What the public records show
CMS Open Payments records show Emerald S Tay, M.D received $224.17 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Kerendia, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.36 | 34.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.18 | 18.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.06 | 12.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.09 | 11.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.79 | 8.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.44 | 7.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.25 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.17 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $58.15 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $41.18 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 91 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
91 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
90 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
26 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 24 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 641 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 103 |
| Omeprazole | Omeprazole | 343 | 79 |
| Metformin Hcl | Metformin Hcl | 290 | 62 |
| Vascepa | Icosapent Ethyl | 261 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 254 | 72 |
| Allopurinol | Allopurinol | 227 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 39 |
| Alendronate Sodium | Alendronate Sodium | 202 | 47 |
| Montelukast Sodium | Montelukast Sodium | 170 | 38 |
| Meloxicam | Meloxicam | 162 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 38 |
| Glimepiride | Glimepiride | 143 | 28 |
| Raloxifene Hcl | Raloxifene Hcl | 132 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 24 |
| Farxiga | Dapagliflozin Propanediol | 120 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 35 |
| Icosapent Ethyl | Icosapent Ethyl | 117 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 26 |
| Atenolol | Atenolol | 109 | 25 |
| Famotidine | Famotidine | 107 | 21 |
| Simvastatin | Simvastatin | 105 | 20 |
| Azithromycin | Azithromycin | 100 | 64 |
| Jardiance | Empagliflozin | 98 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 36 |
| Lidocaine | Lidocaine | 92 | 13 |
| Creon | Lipase/Protease/Amylase | 91 | 18 |
| Linzess | Linaclotide | 90 | 15 |
| Azelastine Hcl | Azelastine Hcl | 86 | 17 |
| Gabapentin | Gabapentin | 85 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 13 |
| Ezetimibe | Ezetimibe | 82 | 14 |
| Clonidine Hcl | Clonidine Hcl | 78 | 21 |
| Finasteride | Finasteride | 77 | 15 |
| Amoxicillin | Amoxicillin | 71 | 44 |
| Latanoprost | Latanoprost | 71 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 65 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 15 |
| Mirtazapine | Mirtazapine | 57 | 16 |
| Lisinopril | Lisinopril | 55 | 11 |
| Meclizine Hcl | Meclizine Hcl | 55 | 23 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 49 | suppressed |
| Ranolazine Er | Ranolazine | 48 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 47 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 44 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Ursodiol | Ursodiol | 41 | suppressed |
| Carvedilol | Carvedilol | 40 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 40 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 13 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Fluocinonide | Fluocinonide | 38 | 13 |
| Ammonium Lactate | Ammonium Lactate | 37 | suppressed |
| Restasis | Cyclosporine | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Nystatin | Nystatin | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Pentoxifylline | Pentoxifylline | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Prolia | Denosumab | 26 | 21 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Naproxen | Naproxen | 23 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 23 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Ketoconazole | Ketoconazole | 21 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Proctozone-Hc | Hydrocortisone | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.17 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LEQVIO, LINZESS, OTEZLA, REPATHA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error